AstraZeneca completes its US$39B buyout deal of Alexion as it sets to expand its portfolio into rare diseases

UK – AstraZeneca has completed its buyout process of Alexion pharmaceuticals in a move that will see the British pharma giant venture extensively into immunology medicines and rare disease therapy. The deal came to fruition just a week after AstraZeneca secured a pivotal nod from the U.K.’s Competition and Markets Authority (CMA). AstraZeneca, Alexion’s now-completed deal stands as a key stepping stone for AstraZeneca as it targets an ambitious sales goal of US$40 billion in just four years, up from the roughly US$26 billion it made in 2020. With the…

Read More

AstraZeneca’s acquisition of Alexion near completion following clearance from European Commission

UK – AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, is finally on course to secure Alexion, a pharma company that specializes in rare disease, following a go-ahead approval from European Commission (EC). The company sought to acquire Alexion for approximately US$39B last year in a bid to establish a specialist rare disease pipeline in its portfolio. EC’s clearance marks an important step towards AstraZeneca’s acquisition of Alexion as the two companies hope to be the leaders in immunology and precision medicines. The proposed acquisition has already received complete clearances…

Read More